Our concept of the pathogenesis of chronic lymphocytic leukemia has undergone
remarkable changes during the past decade. This review addresses the latest ideas …

Abstract Cluster of differentiation 40 (CD40) mediates many immune activities. Preclinical
studies have shown that activation of CD40 can evoke massive antineoplastic effects in …

Due to its relatively slow clinical progression, B cell chronic lymphocytic leukemia (B-CLL) is
classically described as a disease of accumulation rather than proliferation. However …

B cell chronic lymphocytic leukemia (B-CLL) is an accumulative disease of slowly
proliferating CD5+ B lymphocytes that develops in the aging population. Whereas some …

Although it has been well established that osteogenic differentiation of bone mesenchymal
stem cells (bMSCs) as well as osteoclastic differentiation of macrophages can be …

Several studies suggest that immune‐mediated pathways are important in the pathogenesis
of chronic lymphocytic leukaemia (CLL). The in vivo accumulation of leukaemic lymphocytes …

B-cell chronic lymphocytic leukemia (B-CLL) remains an incurable disease that requires
innovative new approaches to improve therapeutic outcome. Honokiol is a natural product …

Death receptors belong to the tumor necrosis factor receptor superfamily and can induce
apoptosis through activation of procaspase-8. The cellular FLICE-inhibitory protein (c-FLIP) …

The mainstay of therapy of chronic lymphocytic leukemia (CLL) is cytotoxic chemotherapy;
however, CLL is still an incurable disease with resistance to therapy developing in the …

Chronic Lymphocytic Leukemia (CLL) B cells display characteristics consistent with a defect
in programmed cell death (apoptosis) and exhibit prolonged survival in vivo. When …